Decoy Therapeutics is trading $3.48 (-5.18%) lower, with no clear company-specific catalyst identified for August 19, 2026.
- Recent Q2 results showed a $2.4 million loss and $228,000 revenue on August 12.
- The broader biotech sector rallied after Moderna’s positive cancer-vaccine trial, making sector weakness an unlikely explanation.
- The decline therefore appears to reflect stock-specific selling or trading dynamics rather than newly reported news.